Patents by Inventor Isin N. Geren

Isin N. Geren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    Patent number: 10611851
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 7, 2020
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Jianlong Lou
  • Antibodies that neutralize botulinum neurotoxins
    Patent number: 10308708
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: June 4, 2019
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20180208679
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
  • Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20170096474
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: August 16, 2016
    Publication date: April 6, 2017
    Inventors: James D. Marks, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Isin N. Geren
  • Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20160168265
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: October 1, 2015
    Publication date: June 16, 2016
    Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
  • Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20150197559
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: February 27, 2015
    Publication date: July 16, 2015
    Inventors: James D. Marks, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Isin N. Geren
  • Antibodies that neutralize botulinum neurotoxins
    Patent number: 9000131
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20140105910
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: September 24, 2013
    Publication date: April 17, 2014
    Applicant: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
  • Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    Patent number: 8598321
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: December 3, 2013
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Jianlong Lou
  • Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20110200615
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: July 30, 2009
    Publication date: August 18, 2011
    Inventors: James D. Marks, Jianlong Lou, Maria Consuelos Garcia Rodriguez, Isin N. Geren
  • THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS
    Publication number: 20100166773
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: March 21, 2008
    Publication date: July 1, 2010
    Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai